RYAH Group Inc. (CSE: RYAH) Sees Important Trends in Sports Medicine and Plant-Therapy

• As U.S. research restrictions are lifted there is a rising interest in the use of plant-therapy in sports medicine
• Cannabis in sports medicine took center stage at the Tokyo Olympics
• American athletes are turning more and more to cannabis as a pain reliever, alternative to opioids, and part of an overall sports recovery plan

RYAH Group (CSE: RYAH) (formerly RYAH Medtech), the leader in dose-control technology for plant-based medicine, works with researchers to provide a full turnkey solution for clinical studies from start to finish. RYAH Group’s dose-control devices standardize the dosing protocol, QR products ensure compliance, and mobile apps collect the necessary data. 

As research restrictions throughout the U.S. lift, RYAH Group is standing by, ready to provide IoT hardware, software, and data analytics that reduce variations in patient-related clinical trials. One of the areas that the U.S. is poised to explore is cannabis in sports medicine. 

Cannabis in sports medicine is a controversial topic and is often not tolerated in professional and collegiate organizations. However, it’s also a topic that took center stage during this year’s Tokyo Olympics. The World Anti-Doping Agency (“WADA”) removing CBD as a prohibited substance in 2017 combined with the 2018 Farm Bill helped change the conversation around CBD use for athletes. As a result, American athletes are turning more and more to cannabis as a pain reliever, alternative to opioids, and part of a recovery plan. 

Megan Rapinoe is an advocate for the use of CBDs in sports recovery. She has incorporated it into her everyday recovery plan but was unable to continue while competing in Tokyo. Rapinoe shared that not being able to take the products she has been using to manage her pain, inflammation, mood, and sleep at the Olympics is “quite frustrating.” 

“We’re expected to perform on the biggest stages and highest levels, yet we can’t use all-natural products to help us recover,” stated Rapinoe (https://ibn.fm/ExEkd). “It’s not right, and these policies need to be changed to reflect where our culture is.”

The NFL is leading the way forward in exploring the benefits of plant-therapy for players. The NFL and the NFL Players Association (“NFLPA”) announced on June 8, 2021, they are investing $1 million in funding for novel pain treatments that include cannabis and CBD therapy (https://ibn.fm/GiVM9). They will be providing five research grants to eligible applicants by November of 2021. 

From 2014 to 2020, the NFL had 801 injures and a 30 percent jump in reported concussions. The NFL is looking for alternatives to opioids, and it seeks out answers to the effectiveness, dosing requirements, and effect of the performance alterations of cannabis. Until now, there hasn’t been studies done regarding sports medicine directly. The NFLPA is changing this. 

Sports organizations across the U.S. must rethink their strict policies with the legalization of recreational and medicinal cannabis across the U.S.

The good news is that with these new studies around plant therapy in sports medicine, a new era of pain management and recovery accepted by sports organizations worldwide may lie right around the corner for athletes like Rapinoe. 

RYAH Group is working alongside researchers globally, providing a holistic approach to therapeutic plant treatment and unlocking the data from seed to consumption. The company’s in-depth analytical reports help to identify significant trends, like the one in sports medicine, in plant therapy

For more information, visit the company’s website at www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.